Statins May Worsen Fatigue in Heart Failure Patients

But no one's suggesting the drugs should be stopped

Posted: November 3, 2009

By Randy Dotinga
HealthDay Reporter

TUESDAY, Nov. 3 (HealthDay News) -- Statins may boost the risk of fatigue and shortness of breath in some patients with heart failure, a new study suggests. But a second report found the cholesterol-reducing drugs reduce the risk of clots in those with cardiovascular disease, and experts think the benefits outweigh the risks.

Dr. Gregg C. Fonarow, a professor of cardiology at the University of California at Los Angeles, said patients shouldn't reconsider their use of the statins based on the results of the small U.S. study.

"Patients with heart failure who have an indication for statin therapy, such as coronary artery disease or diabetes, should remain on physician-prescribed statin therapy," Fonarow said.

At issue is treatment for heart failure, a condition that occurs when the heart fails to beat properly. An estimated 5.7 million people in the United States suffer from heart failure, which can cause fatigue, shortness of breath and fluid build-up in the lungs and legs.

"Approximately two-thirds of patients with heart failure have coronary artery disease," Fonarow said. "In these patients, statins, while not improving overall survival, have been shown to lower the risk of a cardiovascular event and decrease the likelihood of being hospitalized. In patients with heart failure but without vascular disease, neither benefit nor harm has been demonstrated in clinical trials of statin therapy."

Researchers at Northeastern University and Massachusetts General Hospital looked at the medical records of 136 patients with heart failure. They wanted to see how statin use, mainly of the drug atorvastatin (Lipitor), affected two types of heart failure -- systolic and diastolic.

Fonarow explained that the heart fails to contract normally in people with systolic heart failure. In those with diastolic heart failure, the heart may not relax properly or be abnormally stiff, he said.

The study findings were to be released this week at the American College of Chest Physicians annual meeting, in San Diego.

Those who had diastolic heart failure and took a cholesterol drug had almost half as much exercise tolerance as those with the condition who didn't take the drugs, the researchers found.

"Some patients with diastolic heart failure may be more prone to the adverse effect of statins on muscle. It may be that patients with particular preexisting factors will experience unfavorable results from statin therapy, including exercise intolerance, dyspnea [shortness of breath], and fatigue," study author Lawrence P. Cahalin, a researcher at Northeastern University, said in a statement.

"Not all statins are alike, and not all patients are alike. Some statins are stronger than others and are likely to act differently, given particular patient characteristics, and produce different degrees of wanted and unwanted effects," Cahalin said. "In our continuing study, we hope to identify patient characteristics that are associated with favorable and less than favorable results from statin therapy."

For now, Cahalin said tests are in order if heart failure patients taking statins suffer from fatigue, shortness of breath and inability to exercise for very long.

In another study to be released at the meeting, researchers report that statins may help prevent blood clots in people with cardiovascular disease.

Previous research has linked atherosclerosis, a condition in which fatty material builds up along artery walls, and venous thrombosis (VTE). Researchers from Albert Einstein Medical Center in Philadelphia, who were investigating the association between statin use and incidence of VTE, reviewed data on 593 patients who were hospitalized for heart attack or ischemic stroke.

"In our study, statin therapy demonstrated a protective effect on this group of patients, reducing their overall incidence of developing VTE," said study author Dr. Danai Khemasuwan.

Patients in the non-statin group were three times as likely to develop VTE as patients receiving statins, they found.

Given the good news/bad news conclusions of these two reports, patients should not panic, experts said. Statins provide significant benefits for patients with cardiovascular disease, Dr. Kalpalatha Guntupalli, president of the American College of Chest Physicians, said in a statement. However, as for any new medication prescribed, clinicians should closely monitor the effects that different types of statins have on individual patients.

Cholesterol Reduction and Health Problems - new review of research

Cholesterol-lowering therapy and cell membranes. Stable

plaque at the expense of unstable membranes?

Glyn Wainwright1, Luca Mascitelli2, Mark R. Goldstein3

A b s t r a c t

Current guidelines encourage ambitious long term cholesterol lowering with

statins, in order to decrease cardiovascular disease events. However, by

regulating the biosynthesis of cholesterol we potentially change the form and

function of every cell membrane from the head to the toe. As research into cell

morphology and membrane function realises more dependencies upon

cholesterol rich lipid membranes, our clinical understanding of long term

inhibition of cholesterol biosynthesis is also changing. This review of noncardiovascular

research concerning such membrane effects raises important

new issues concerning the clinical advantages and disadvantages of the long

term use, and broadening criteria, of cholesterol reductions.

Key words: cholesterol, exocytosis, lipid, membrane, statin.

Introduction

The undoubted commercial success story in modern medicine has been

the creation of that infamous household dietary and medical obsession:

‘Cholesterol’. Over the past decade researchers have achieved new insight

into the regulatory relationship between cholesterol and the world of lipid

transport.

A persuasive association of statistics about cardiovascular outcomes

and levels of blood plasma lipids has created a sophisticated range of

therapeutic targets for cholesterol lowering therapies [1].

Statin drugs are extensively used and are very effective in lowering

serum low-density lipoprotein cholesterol [2]. They have been shown to

reduce the incidence of cardiovascular events especially in secondary

prevention, although there is reason to believe that most of their effects

are mediated in spite of their cholesterol lowering action [3].

De-novo cholesterol, the target of statin therapy, is found in all

membranes and lipid based bodies, where it is now known to be vital to

their proper structure and operation. Ikonen’s excellent review of

‘cholesterol trafficking’ [4] summarises the processes and mechanisms by

which cholesterol contributes to vesicle formation, migrations and

membrane functions throughout the cellular apparatus, and also illustrates

the importance of cholesterol homeostasis. The function and adequacy of

cholesterol in lipid membranes directly influences the production, secretion,

delivery and utilisation of every lipoprotein [5].

www.termedia.pl/ams

G Wainwright @ Nov 04, 2009 10:23:38 AM

Add Your Thoughts
About You

advertisement

U.S. News Rankings & Research

Best Hospitals

See the best hospitals, and the best children's hospitals, in specialties from cancer to urology.

Best Health Plans

U.S. News and NCQA review over 700 health insurance plans in the Best Health Plan rankings.

Best Nursing Homes

The Best Nursing Homes rankings feature data on 15,000-plus homes. Search for one near you.

Diseases & Conditions

Get information on preventing, treating, and managing diseases and conditions. Centers:

advertisement

Sponsored Poll

What factor do you think is responsible for the majority of teen-driving crashes?

View Results

advertisement

Subscribe

U.S. News Digital Weekly

A weekly insider's guide to politics and policy — in a multimedia, digital format. 52 issues for $19.95!

U.S. News & World Report

6 months of U.S. News & World Report's print edition for only $15. Save up to 67% off the cover price!